Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESSINA benralizumab study in eosinophilic esophagitis
NL-OMON55048Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Benralizumab with Placebo (2 arms). Primary endpoints: Histologic response at Week 24 and Change from baseline in DSQ score at Week 24. Started Nov 2020; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON55048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55048.